Abstract
The New York State Attorney General's office is heralding a “new standard of disclosure” for clinical trial findings after reaching an agreement with GlaxoSmithKline to settle a lawsuit that alleged GSK committed consumer fraud by concealing studies indicating the antidepressant paroxetine could

This publication has 0 references indexed in Scilit: